NO314035B1 - Tiolsulfonamidmetalloproteaseinhibitorer, farmasöytisk sammensetning innbefattende samme og anvendelse av samme for fremstilling avmedikament - Google Patents

Tiolsulfonamidmetalloproteaseinhibitorer, farmasöytisk sammensetning innbefattende samme og anvendelse av samme for fremstilling avmedikament Download PDF

Info

Publication number
NO314035B1
NO314035B1 NO19990247A NO990247A NO314035B1 NO 314035 B1 NO314035 B1 NO 314035B1 NO 19990247 A NO19990247 A NO 19990247A NO 990247 A NO990247 A NO 990247A NO 314035 B1 NO314035 B1 NO 314035B1
Authority
NO
Norway
Prior art keywords
alkyl
group
mmol
optionally substituted
substituents selected
Prior art date
Application number
NO19990247A
Other languages
English (en)
Norwegian (no)
Other versions
NO990247D0 (no
NO990247L (no
Inventor
Gary Decrescenzo
Zaheer Abbas
John N Freskos
Daniel P Getman
Robert M Heintz
Brent V Mischke
Joseph J Mcdonald
Original Assignee
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Co filed Critical Monsanto Co
Publication of NO990247D0 publication Critical patent/NO990247D0/no
Publication of NO990247L publication Critical patent/NO990247L/no
Publication of NO314035B1 publication Critical patent/NO314035B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
    • C07C323/49—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO19990247A 1996-07-22 1999-01-20 Tiolsulfonamidmetalloproteaseinhibitorer, farmasöytisk sammensetning innbefattende samme og anvendelse av samme for fremstilling avmedikament NO314035B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2204096P 1996-07-22 1996-07-22
PCT/US1997/012873 WO1998003166A1 (en) 1996-07-22 1997-07-22 Thiol sulfonamide metalloprotease inhibitors

Publications (3)

Publication Number Publication Date
NO990247D0 NO990247D0 (no) 1999-01-20
NO990247L NO990247L (no) 1999-03-19
NO314035B1 true NO314035B1 (no) 2003-01-20

Family

ID=21807509

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19990247A NO314035B1 (no) 1996-07-22 1999-01-20 Tiolsulfonamidmetalloproteaseinhibitorer, farmasöytisk sammensetning innbefattende samme og anvendelse av samme for fremstilling avmedikament

Country Status (14)

Country Link
EP (1) EP0939629A4 (cs)
JP (1) JP2000515153A (cs)
KR (1) KR20000067964A (cs)
CN (1) CN1238688A (cs)
AU (1) AU740263C (cs)
BR (1) BR9710752A (cs)
CA (1) CA2260860A1 (cs)
CZ (1) CZ16899A3 (cs)
IL (1) IL128080A0 (cs)
NO (1) NO314035B1 (cs)
NZ (1) NZ333825A (cs)
PL (1) PL331338A1 (cs)
RU (1) RU2202540C2 (cs)
WO (1) WO1998003166A1 (cs)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1029541B1 (en) * 1997-07-22 2006-03-22 Shionogi & Co., Ltd. Therapeutic or prophylactic agent for glomerulopathy
CA2344412A1 (en) 1998-09-21 2000-03-30 Takeda Chemical Industries, Ltd. Thiol compound, their production and use
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
BR0007784A (pt) 1999-01-27 2002-02-05 American Cyanamid Co Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
ATE280152T1 (de) * 1999-01-27 2004-11-15 Wyeth Corp Acetylenische sulfonamid-thiol-tace-inhibitoren
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
NZ514453A (en) * 1999-02-26 2003-04-29 Merck & Co Inc Novel sulfonamide compounds and uses thereof
WO2000063194A1 (fr) * 1999-04-19 2000-10-26 Shionogi & Co., Ltd. Derives de sulfonamide possedant des noyaux oxadiazole
WO2001005389A2 (en) * 1999-07-16 2001-01-25 G.D. Searle & Co. N-sulfonylaminiacid derivatives as inhibitors of metalloprteinase
US6869951B1 (en) 1999-07-16 2005-03-22 Pharmacia Corporation Method of changing conformation of a matrix metalloproteinase
EP1088815A1 (en) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
WO2001077092A1 (en) * 2000-04-07 2001-10-18 Samsung Electronics Co., Ltd. Sulfonamide derivative as a matrix metalloproteinase inhibitor
AU2000265100A1 (en) * 2000-07-12 2002-01-21 G.D. Searle And Co. N sulfonyl aminoacid derivatives as inhibitors of metalloproteinase
US6657070B2 (en) 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
US6610734B2 (en) 2000-12-13 2003-08-26 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production
WO2002100846A1 (en) * 2001-06-11 2002-12-19 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
CN1610661A (zh) 2001-11-01 2005-04-27 惠氏控股公司 用作基质金属蛋白酶和tace的抑制剂的丙二烯芳基磺酰胺异羟肟酸
GEP20063920B (en) * 2001-12-20 2006-09-11 Bristol Myers Squibb Co Alpha-(n-sulphonamido) acetamide derivatives as beta-amyloid inhibitors
MXPA04012313A (es) * 2002-06-11 2005-02-25 Arqule Inc Compuestos de fenilsulfonamida sustituida inhibidores de la produccion de beta-amiloide.
WO2005021489A2 (en) 2002-12-23 2005-03-10 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
EP1449538A1 (en) * 2003-02-21 2004-08-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation
AR043940A1 (es) 2003-03-31 2005-08-17 Wyeth Corp Inhibidores de sulfonamidas heterociclicas que contienen fluor- y trifluoralquilo de la produccion de beta amiloides y derivados de los mismos
EP1493740A1 (fr) * 2003-07-03 2005-01-05 Warner-Lambert Company LLC Dérivés de 5-fluoro-thiophene, leur procédé de preparation, les compositions pharmaceutiques les contenant et leur utilisation comme inhibiteurs de métalloprotéinases
WO2005090296A2 (en) * 2004-03-11 2005-09-29 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
EP1757591A4 (en) 2004-05-26 2010-05-05 Eisai R&D Man Co Ltd ZIMTSÄUREAMIDVERBINDUNG
GB0412553D0 (en) * 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
ITFI20040174A1 (it) * 2004-08-03 2004-11-03 Protera S R L Derivati arilsolfonammidici dell'acido idrossammico ad azione inibitoria di metalloproteinasi
ES2338904T3 (es) 2004-10-26 2010-05-13 EISAI R&D MANAGEMENT CO., LTD. Forma amorfa de compuestos de cinamida.
WO2006062093A1 (ja) * 2004-12-07 2006-06-15 Toyama Chemical Co., Ltd. 新規なアントラニル酸誘導体またはその塩
US7595327B2 (en) 2005-03-21 2009-09-29 Wyeth Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase
WO2007060810A1 (ja) 2005-11-24 2007-05-31 Eisai R & D Management Co., Ltd. モルホリンタイプ・シンナミド化合物
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
SA07280403B1 (ar) 2006-07-28 2010-12-01 إيساي أر أند دي منجمنت كو. ليمتد ملح رباعي لمركب سيناميد
CL2008000582A1 (es) 2007-02-28 2008-06-27 Eisai R&D Man Co Ltd Compuestos ciclicos derivados de oximorfolina condensados; farmacos que comprenden a dichos compuestos; y su uso para tratar enfermedad de alzheimer, demencia senil, sindrome de down o amiloidosis.
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
WO2009028588A1 (ja) 2007-08-31 2009-03-05 Eisai R & D Management Co., Ltd. 多環式化合物
US8093276B2 (en) 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8084477B2 (en) 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
EP2149568A1 (en) * 2008-07-22 2010-02-03 Bracco Imaging S.p.A Aryl-sulphonamidic dimers as metalloproteases inhibitors
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TW201141536A (en) * 2009-12-21 2011-12-01 Colgate Palmolive Co Oral care compositions and methods
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
AU2015367528B2 (en) 2014-12-17 2020-05-14 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
WO2017117130A1 (en) 2015-12-28 2017-07-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU540862A1 (ru) * 1975-02-10 1976-12-30 Предприятие П/Я М-5593 2,2"Бис(диэтаноламин)-диалкил(арил) дисульфиды, в качестве антифрикционных и противозадирно-противоизносных присадок к смазочным материалам, и способ их получени
US4595700A (en) * 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9307956D0 (en) * 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
HUT77282A (hu) * 1994-10-05 1998-03-30 Darwin Discovery Limited Peptidvegyületek és gyógyászati alkalmazásuk metalloproteáz inhibitorokként

Also Published As

Publication number Publication date
AU3890397A (en) 1998-02-10
NZ333825A (en) 2000-10-27
EP0939629A4 (en) 2002-07-17
AU740263B2 (en) 2001-11-01
CZ16899A3 (cs) 1999-08-11
RU2202540C2 (ru) 2003-04-20
JP2000515153A (ja) 2000-11-14
EP0939629A1 (en) 1999-09-08
CN1238688A (zh) 1999-12-15
BR9710752A (pt) 1999-08-17
NO990247D0 (no) 1999-01-20
NO990247L (no) 1999-03-19
CA2260860A1 (en) 1998-01-29
KR20000067964A (ko) 2000-11-25
AU740263C (en) 2002-05-16
IL128080A0 (en) 1999-11-30
WO1998003166A1 (en) 1998-01-29
PL331338A1 (en) 1999-07-05

Similar Documents

Publication Publication Date Title
NO314035B1 (no) Tiolsulfonamidmetalloproteaseinhibitorer, farmasöytisk sammensetning innbefattende samme og anvendelse av samme for fremstilling avmedikament
ES2236893T3 (es) Compuestos de acido sulfonamida hidroxamico con anillo amidoaromatico.
JP4091654B2 (ja) レトロウイルスプロテアーゼ阻害剤として有用なスルホニルアルカノイルアミノヒドロキシエチルアミノスルホンアミド
AU714687B2 (en) Thiol sulfone metalloprotease inhibitors
AU750130B2 (en) Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds
CZ20012636A3 (cs) Sulfonamidhydroxamové kyseliny na bázi acetylenové alfa-aminokyseliny jako inhibitory TACE
MXPA01011569A (es) Acido sulfona hidroxamico inhibidor de metaloproteasa.
MXPA04000388A (es) Hidroximatos de sulfonilarilo y su uso como inhibidores de metaloproteinasas matriciales.
MXPA01011481A (es) Derivados de acido hidroxamico como inhibidores de metaloproteasas de la matriz.
MXPA01011865A (es) Compuestos de acido a-amino-b-sulfonil hidroxamico.
US6747027B1 (en) Thiol sulfonamide metalloprotease inhibitors
AU6712001A (en) Thiol sulfonamide metalloprotease inhibitors
NZ506464A (en) Salts of thiol sulfonamide inhibitors for matrix metalloproteinase 13 (MMP-13)
US20040034071A1 (en) Thioaryl sulfonamide hydroxamic acid compounds
CZ310899A3 (cs) N-hydroxy-4-sulfonylbutanamidové sloučeniny